Published:  11:54 AM, 09 September 2021

Nerve disorder listed as 'very rare' side effect of AstraZeneca jab

Nerve disorder listed as 'very rare' side effect of AstraZeneca jab


The European Medicines Agency has
listed the neurological disorder Guillain-Barre syndrome, which can cause
temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19
vaccine.

  A causal relationship was "considered at least a reasonable possibility",
the EMA said in an update Wednesday after a total of 833 cases of the
syndrome had been reported worldwide by July 31, from about 592 million doses
of the AstraZeneca "Vaxzevria" shot administered.

  "GBS should therefore be added to the product information as a side effect
of Vaxzevria," the Amsterdam-based agency said.

  Guillain-Barre Syndrome was a "very rare" side effect, occurring in under
one in 10,000 people, it added.

  The disorder is a nerve inflammation that may cause temporary paralysis and
difficulty breathing.

  In the United States, the very rare syndrome affects an estimated 3,000 to
6,000 people each year and most go on to recover.

  The EMA recommended that a warning be added to information on the vaccine
that tells people to seek medical attention if they develop weakness and
paralysis in the extremities that can progress to the chest and face.

  The European drug regulator had in July listed Guillain-Barre syndrome as a
"very rare" side effect of the Johnson & Johnson vaccine, which uses the same
adenovirus technology as the AstraZeneca jab.

  The US Food and Drug Administration also warned in July of an "increased
risk" of developing the neurological syndrome with Johnson & Johnson's dose.

  Both regulators stressed that the vaccine's benefits outweighed the
potential risks.




Latest News


More From Health

Go to Home Page »

Site Index The Asian Age